Physician profile
Clarissa Liew
NPI 1942495494
$9,311.93
in general payments reported to CMS, 2019-2025
55 companies · $2,206 in 2025
The $2,206 reported for 2025 was more than what 77% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $97.27 · 2021: $149 · 2022: $1,121 · 2023: $1,460 · 2024: $3,138 · 2025: $2,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,667 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,666.78 |
| Education | $136.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,155.76 | 2022-2025 | Inspire |
| Abbvie INC. | $830.79 | 2019-2025 | |
| Lilly USA, LLC | $476.94 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Supernus Pharmaceuticals, INC. | $453.17 | 2019-2024 | Qelbree |
| Novartis Pharmaceuticals Corporation | $373.69 | 2019-2025 | |
| Catalyst Pharmaceuticals, INC. | $372.02 | 2022-2025 | Fycompa |
| Lundbeck LLC | $368.95 | 2023-2025 | Vyepti |
| Genentech USA, INC. | $349.20 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Biogen, INC. | $325.15 | 2019-2025 | Tysabri, Vumerity |
| Teva Pharmaceuticals USA, INC. | $308.74 | 2019-2025 | Austedo Xr, Austedo Xr |
| Grifols USA, LLC | $307.20 | 2019-2025 | Gamunex-C |
| Eisai INC. | $302.27 | 2023-2025 | |
| Sk Life Science, INC. | $273.93 | 2020-2025 | |
| Pfizer INC. | $268.12 | 2019-2025 | |
| Ucb, INC. | $264.75 | 2019-2025 | Zilbrysq, Briviact, Nayzilam |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarissa Liew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.